More News

18 Jan 2022 City of Hope and CytoImmune announce study demonstrating novel off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell-based therapy against pancreatic cancer
18 Jan 2022 Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
18 Jan 2022 Almirall and IRB Barcelona announce a research collaboration to discover novel molecular glue therapeutics for severe skin diseases
13 Jan 2022 ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme
13 Jan 2022 AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets
12 Jan 2022 Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
12 Jan 2022 Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer
12 Jan 2022 Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals
12 Jan 2022 Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals
12 Jan 2022 NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics
12 Jan 2022 ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease
10 Jan 2022 Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
10 Jan 2022 Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
10 Jan 2022 TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio
10 Jan 2022 Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
10 Jan 2022 Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
10 Jan 2022 Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
10 Jan 2022 Bayer and Mammoth Biosciences to collaborate on novel gene editing technology
08 Jan 2022 Absci Announces Research Collaboration with Merck
07 Jan 2022 Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
07 Jan 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
07 Jan 2022 Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
06 Jan 2022 Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement
06 Jan 2022 Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications
06 Jan 2022 POLARISqb and PhoreMost announce a multi-target collaboration to investigate next-generation cancer therapies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top